Skip to main content

Advertisement

Table 2 MMRM results for ADAS-cog13 at week 6 (visit 3) and week 12 (visit 5)

From: A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil

Visit Treatment group n LS mean (SE) 80% CI Difference (SE) 80% CI for difference Two-sided P value
Week 6 SAM-760 84 −0.71 (0.50) −1.36, −0.06 0.74 (0.70) −0.16, 1.64 0.29
Placebo 93 −1.45 (0.48) −2.06, −0.83
Week 12 SAM-760 78 0.11 (0.63) −0.70, 0.92 0.70 (0.87) −0.42, 1.82 0.43
Placebo 86 −0.58 (0.60) −1.36, 0.19
  1. ADAS-cog13 Alzheimer’s Disease Assessment Scale-cognitive subscale, CI confidence interval, LS least squares, MMRM mixed model repeated measures, SE standard error